PTA-CMS: QIAGEN N.V.: Release of a capital market information

QIAGEN N.V. disclosed that BlackRock holds 11.87% capital interest and 13.18% voting rights in the company, according to an AFM filing. No prior-period comparison was provided. The disclosure is a regulatory ownership update, not an earnings or operating report.

QIAGEN N.V. (QGEN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Media Release QIAGEN reports full Q3 2026 results • Q3 2026 results: ◦ Net sales of $548 million rise 3% and also 3% at constant exchange rates (CER) ◦ Adjusted operating income margin of 30.4% rises 0.8 percentage points ◦ Diluted EPS of $0.51; adjusted diluted EPS

Qiagen (QGEN) reported Q3 sales across various product groups, with most figures close to analyst estimates. Key products like QIAstat-Dx and QuantiFERON saw mixed year-over-year changes, ranging from -22.2% to +10%.

Qiagen (QGEN) reported Q3 earnings of $0.65 per share, beating estimates by $0.02. Revenue was $547.87 million, exceeding expectations by 1.56%. The company has surpassed EPS and revenue estimates three times in the last four quarters. Shares have risen 6.4% YTD. The Zacks Rank #2 (Buy) suggests potential outperformance.

Qiagen N.V. reported Q3 sales and adjusted EPS above prior forecasts, driven by pillar growth and sample technologies. The company suspended 2026 guidance due to a pending €46.50-per-share takeover offer from EQT. According to the company, the offer is under review.

JPMorgan Chase & Co. reported a 4.73% stake in QIAGEN N.V. as of Oct. 27, 2026, according to an AFM notification. No prior-period comparison was provided.